Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012

      -- Company to provide product pipeline update on conference call at 5 PM ET today --


      News provided by

      Verenium Corporation

      Aug 06, 2012, 04:00 ET

      Share this article

      Share this article


      SAN DIEGO, Aug. 6, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported operating highlights and financial results for the second quarter and six months ended June 30, 2012.

      "The first half of the year proved to be an important turning point for Verenium," said James Levine, President & Chief Executive Officer at Verenium.  "With the recent move into our new facility completed and our debt repaid, we are focused on growing our business through the sales of our current marketed products, developing our product pipeline, and establishing future collaborations and partnerships."

      Company Highlights

      Since the beginning of 2012, the Company has made progress on both operational and financial fronts.  Recent accomplishments include:

      • Completed a strategic transaction with DSM Food Specialties, B.V. ("DSM"), including the sale of the Company's oilseed processing business, for total consideration of $37 million;
      • Repurchased $34.9 million in convertible notes outstanding, retiring all of the Company's remaining debt;
      • Announced that the Company's next-generation enzyme breaker was authorized for use in hydraulic fracturing by the Environmental Protection Agency (EPA);
      • Completed moving into the Company's new office and state-of-the-art laboratory and pilot plant facility in San Diego, California; and
      • Ended the second quarter with unrestricted cash of $14.4 million and $5.7 million in restricted cash.

      Financial Results

      In the commentary below, the operating results of the Company's oilseed processing business, sold to DSM in March 2012, for prior periods are included in continuing operations.

      Revenues

      Revenues for the periods ended June 30, 2012 and 2011 were as follows (in thousands):


      Three Months Ended 

      June 30,


      Six Months Ended 

      June 30,


      2012


      2011


      2012


      2011

      Revenues:








             Animal health and nutrition

      $      9,256


      $      8,035


      $     16,672


      $     16,110

             Grain processing

      2,256


      4,535


      5,841


      8,429

             Oilseed processing

      --


      1,629


      579


      2,612

             All other products

      730


      279


      871


      359

      Total product

      12,242


      14,478


      23,963


      27,510

      Contract manufacturing (1)

      2,486


      --


      2,486


      --

      Collaborative and license

      969


      656


      6,477


      1,020

      Total revenue

      $     15,697


      $    15,134


      $     32,926


      $     28,530



      (1)

      Revenue from the DSM supply agreement is reported as contract manufacturing, revenue for Purifine and Veretase prior to the DSM transaction are reflected in oilseed processing and grain processing revenue, respectively.

      Total revenues for the six months ended June 30, 2012 increased 15% to $32.9 million from $28.5 million for the same period in the prior year.  Product and contract manufacturing revenues represented approximately 80% of total revenues for the six months ended June 30, 2012 compared to 96% for the same period in the prior year.

      Product revenue for the six months ended June 30, 2012 decreased 13% to $24.0 million from $27.5 million for the same period in the prior year, primarily due to a decrease in grain processing revenue compared to 2011 due primarily to adverse business conditions in the corn ethanol industry and the sale of the Company's Purifine and Veretase products to DSM in March of 2012.  The decrease was partially offset by an increase in Phyzyme phytase revenue due to increased manufacturing volumes, as well as an increase in profit share from Dupont.

      Product and contract manufacturing revenue from non-Phyzyme products as a percentage of total product and contract manufacturing revenues decreased to 37% for the six months ended June 30, 2012 compared to 51% for the same period in the prior year.

      Contract manufacturing revenue increased as a result of the supply agreement entered into in conjunction with the DSM sale, under which to the Company produces and sells Purifine and Veretase to DSM at lower sales prices than when the Company sold directly to end customers.

      Total collaborative revenue for the six months ended June 30, 2012 increased to $6.5 million from $1.0 million for the same period in the prior year, primarily due to recognition of the $2.9 million license fee revenue from Novus International, Inc., and $1.5 million in license fees associated with the DSM transaction.  The Company also generated $0.5 million in revenue from a one-time up-front payment associated with the development of a commercial product under an agreement with Tate & Lyle.

      Product and Contract Manufacturing Gross Profit and Gross Margin

      Product and contract manufacturing gross profit for the six months ended June 30, 2012 decreased 8% to $9.2 million from $10.0 million for the same period in the prior year. Gross margin decreased to 35% of total product and contract manufacturing revenue for the six months ended June 30, 2012, compared to 36% for the six months ended June 30, 2011.  Gross margin decreased primarily due to the Company's supply agreement with DSM, under which the Company sells Purifine and Veretase enzymes at a lower margin.

      Operating Expenses (excluding cost of product and contract manufacturing revenue and restructuring expense)

      Excluding cost of product and contract manufacturing revenues and restructuring charges, total operating expenses related to continuing operations for the six months ended June 30, 2012 increased to $17.4 million (including share-based compensation of $0.4 million) from $14.1 million (including share-based compensation of $0.3 million) for the same period in the prior year.  This increase is primarily due to reimbursement of $1.1 million of legal fees during the first quarter of 2011 associated with the settlement of a noteholder lawsuit, which was recorded as an offset to operating expenses.  In addition, operating expenses were elevated during the first quarter of 2012 for transaction costs associated with various financing alternatives the Company was pursuing. Overall, after the effect of the prior year legal fee reimbursement, ongoing general and administrative expenses have remained flat over the prior year, while research and development costs have increased, reflecting continued investment in pipeline products.

      Gain on Sale of Oilseed Processing Business

      On March 23, 2012, the Company entered into an asset purchase agreement with DSM for the purchase of the Company's oilseed processing business and concurrently entered into a license agreement, a supply agreement and a transition services agreement with DSM.  The aggregate consideration received by the Company was $37 million.  The gain on sale for the six months ended June 30, 2012 was calculated as the difference between the allocated consideration amount for the oilseed processing business, in accordance with authoritative accounting guidance, of $31.3 million and the net carrying amount of the purchased assets and liabilities and transaction costs.

      Income (Loss) from Operations

      Income from operations for the six months ended June 30, 2012 was $29.6 million compared to loss from operations of $6.0 million for the same period in 2011, on a GAAP accounting basis.  Adjusted for the impact of restructuring expenses and the gain on sale of the oilseed business of $31.3 million, the Company's non-GAAP pro-forma loss from operations was $1.7 million for the six months ended June 30, 2012 compared to $3.0 million for the same period in 2011.  The Company believes that excluding the impact of these items provides a more consistent measure of operating results.

      Net Income from Continuing Operations

      Net income from continuing operations for the six months ended June 30, 2012 was $27.7 million compared to $2.3 million for the same period in 2011, on a GAAP accounting basis. Adjusted for the impact of restructuring expenses, non-cash items related to the Company's convertible debt and gain on sale of its oilseed processing business, the Company's non-GAAP pro-forma net loss from continuing operations for the six months ended June 30, 2012 was $2.8 million compared to $4.8 million for the same period in the prior year. The Company believes that excluding the impact of these items provides a more consistent measure of operating results. 

      Balance Sheet

      The Company ended the quarter with $14.4 million in cash and cash equivalents and $5.7 million in total restricted cash.  On April 2, 2012, the Company repurchased the remaining $34.9 million in principal amount of its outstanding 5.5% convertible notes.  To effect these repurchases, the Company paid a total of $35.8 million in cash to its noteholders, including accrued and unpaid interest.  The Company has no remaining debt as of June 30, 2012.

      "Despite adverse conditions in the corn ethanol industry, we are pleased overall with our financial results for the first half of 2012," said Jeffrey Black, Senior Vice President and Chief Financial Officer.  "As we aggressively push to increase customer adoption rates, grow our top line and improve product gross margins, we continue to maintain our focus on prudent cost management and cash conservation."

      Conference Call and Webcast

      The Company will host a conference call with live webcast on Monday, August 6 at 5:00 p.m. ET.  The call may be accessed by dialing 877-755-7422 (domestic) or 678-894-3067 (international) five minutes prior to start time and providing the passcode 11868063.  A link to the live webcast and the slides included in the webcast may also be accessed by visiting the "Investors" section of the Company's website at http://ir.verenium.com/.  A replay of the event will be available on the Company's website approximately two hours after the call and will be archived for 30 days.

      About Verenium

      Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

      Forward-Looking Statements

      Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates and product pipeline, lines of business, operations (including Verenium's ability to successfully negotiate and enter into future collaborations and partnerships), capabilities, commercialization activities, customer adoption rates, industry conditions, future financial performance, and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

      Contacts:

      Sarah Carmody

      Manager, Corporate Communications

      858-431-8581

      [email protected]




      Verenium Corporation

      Condensed Consolidated Statements of Operations

      (unaudited, in thousands, except per share amounts)






      Three Months Ended

      June 30,


      Six Months Ended

      June 30,


      2012


      2011


      2012


      2011

      Revenues:








         Product

      $  12,242


      $ 14,478


      $  23,963


      $ 27,510

         Contract manufacturing

      2,486


      --


      2,486


      --

         Collaborative and license

      969


      656


      6,477


      1,020

      Total revenue

      15,697


      15,134


      32,926


      28,530









      Operating expenses:








         Cost of product and contract

         manufacturing revenue

      9,921


      9,392


      17,236


      17,476

      Product and contract

      manufacturing gross profit

      4,807


      5,086


      9,213


      10,034

      Product and contract

      manufacturing gross margin

      33%


      35%


      35%


      36%

         Research and development

      3,880


      2,288


      7,041


      4,920

         Selling, general and administrative

      4,428


      4,666


      10,356


      9,166

         Restructuring charges

      9


      82


      16


      2,920

      Total operating expenses

      18,238


      16,428


      34,649


      34,482









      (Gain) loss on sale of oilseed

      processing business

      203


      --


      (31,278)


      --









      Income (loss) from operations

      (2,744)


      (1,294)


      29,555


      (5,952)









      Other income and expense:








         Interest and other expense, net

      (43)


      (692)


      (1,052)


      (1,753)

      Gain on debt extinguishment upon

      repurchase of convertible notes

      --


      --


      --


      11,284

          Gain (loss) on net change in fair

          value of derivative assets and

          liabilities

      232


      518


      (92)


      (1,295)

      Total other income (expense), net

      189


      (174)


      (1,144)


      8,236









      Net income (loss) from continuing

      operations before income taxes

      (2,555)


      (1,468)


      28,411


      2,284

      Income tax benefit (provision)

      87


      --


      (742)


      --

      Net income (loss) from continuing

      operations

      (2,468)


      (1,468)


      27,669


      2,284

       Net Income (loss) from discontinued

       operations

      (11)


      --


      (26)


      61

      Net income (loss) attributed to Verenium

      $   (2,479)


      $ (1,468)


      $     27,643


      $    2,345

      Net income (loss) per share, basic:








      Continuing operations

      $     (0.20)


      $   (0.12)


      $        2.19


      $     0.18

      Discontinued operations

      $          --


      $        --


      $            --


      $         --

      Attributed to Verenium Corporation

      $     (0.20)


      $   (0.12)


      $        2.19


      $     0.19

      Net income (loss) per share, diluted:








           Continuing operations

      $     (0.20)


      $   (0.12)


      $        2.15


      $     0.18

      Discontinued operations

      $          --


      $        --


      $            --


      $         --

      Attributed to Verenium Corporation

      $     (0.20)


      $   (0.12)


      $        2.14


      $     0.19









      Shares used in computing net income

      (loss) per share, basic

      12,618


      12,606


      12,614


      12,606

      Shares used in computing net income

      (loss) per share, diluted

      12,618


      12,606


      13,117


      12,606



      Verenium Corporation

      Condensed Consolidated Balance Sheet Data

      (in thousands)






      June 30,


      December 31,


      2012

      (unaudited)


      2011





      Cash and cash equivalents

      $      14,357


      $        28,759

      Restricted cash, short term

      2,500


      5,000

      Accounts receivable, net

      10,017


      11,371

      Inventories, net

      5,483


      6,323

      Other current assets 

      2,560


      2,396

      Restricted cash, long term

      3,200


      3,200

      Property and equipment, net 

      13,502


      7,806

      Other noncurrent assets 

      692


      482





      Total assets 

      $       52,311


      $       65,337









      Accounts payable and accrued expenses

      $       10,938


      $       15,062

      Other short term liabilities

      291


      436

      Deferred revenue, current 

      1,813


      4,137

      Convertible notes

      --


      34,851

      Other long term liabilities 

      792


      906

      Stockholders' equity 

      38,477


      9,945





      Total liabilities and

          stockholders' equity 

      $          52,311


      $       65,337






      Verenium Corporation

      Unaudited Supplemental and Non-GAAP Pro Forma Financial Information

      (in thousands, except per share amounts)


      The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's condensed consolidated financial statements for the three and six months ended June 30, 2012 and 2011, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business.


      Non-GAAP Pro Forma Income (Loss) From Operations



      Three Months Ended

      June 30,


      Six Months Ended

      June 30,


      2012


      2011


      2012


      2011



       Income (loss) from operations

      $   (2,744)


      $   (1,294)


      $   29,555


      $   (5,952)









      Adjustments: 








      (Gain) loss on sale of

      oilseed processing business

      203


      --


      (31,278)


      --

      Restructuring charges

      9


      82


      16


      2,920

      Non-GAAP pro forma loss

      from operations 

      $  (2,532)


      $   (1,212)


      $   (1,707)


      $    (3,032)

      Non-GAAP Pro Forma Net Income (Loss) From Continuing Operations



      Three Months Ended

      June 30,


      Six Months Ended

      June 30,


      2012


      2011


      2012


      2011

       Net income (loss) from

       continuing operations

      $   (2,468)


      $      (1,468)


      $    27,669


      $    2,284









      Adjustments: 








      Gain (loss) on sale of oilseed

      processing business

      203


      --


      (31,278)


      --

      Restructuring charges

      9


      82


      16


      2,920

      Income tax (benefit) provision

      (attributed to sale of oilseed

      processing business)

      (87)


      --


      742


      --

      Gain on debt extinguishment

      upon repurchase of convertible notes

      --


      --


      --


      (11,284)

      (Gain) loss on net change in

      fair value of derivative assets and

      liabilities

      (232)


      (518)


      92


      1,295

      Non-GAAP pro forma net loss

      from continuing operations 

      $  (2,575)


      $        (1,904)


      $    (2,759)


      $   (4,785)

      Non-GAAP pro forma net loss

      from continuing operations per

      share, basic 

      $    (0.20)


      $          (0.15)


      $      (0.22)


      $     (0.38)

      SOURCE Verenium Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.